The key vulnerabilities and therapeutic opportunities in the USP7-p53/MDM2 axis in cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The MDM2/MDMX-p53 pathway regulates critical cancer cell processes like apoptosis and proliferation.
• USP7 (ubiquitin-specific protease 7) is a key regulator of p53, MDM2, and MDMX stability.
• The USP7-p53-MDM2/MDMX axis influences p53 levels and function in cancer.

Purpose of the Study:

• To explore the therapeutic potential of targeting USP7 in cancer treatment.
• To investigate USP7's role in both wild-type p53 (Wt-p53) and mutant p53 (Mut-p53) cancers.

Main Methods:

• Analysis of the USP7-p53-MDM2/MDMX regulatory network.
• In silico or experimental validation of USP7 inhibition effects on cancer cells with different p53 statuses.

Main Results:

• In Wt-p53 tumors, USP7 inhibition triggers MDM2/MDMX degradation, activating p53 and inducing cell cycle arrest and apoptosis.
• Targeting USP7 in Mut-p53 tumors is less explored due to USP7's diverse targets.
• Mut-p53's resistance to degradation suggests USP7 might stabilize it, warranting further investigation.

Conclusions:

• USP7 inhibition is a potential cancer therapy strategy, particularly for Wt-p53 tumors.
• USP7 stabilization of Mut-p53 is a hypothesis requiring further research.
• USP7 could be a therapeutic target in both Wt-p53 and Mut-p53 cancers.